Should you be taking peptides?
Even a pro-peptide researcher has one big reservation
Levels <[email protected]>
Share
Levels promotes a discussion on the science behind peptides, featuring an interview with Dr. Christopher Robinson, a Johns Hopkins physician-scientist. The company highlights the lack of human evidence for popular peptides like BPC-157 and notes that many are repurposed or abandoned drugs. Levels presents five key takeaways to educate readers on the peptide market.
What the raw message shows
From the headers
- Sent with
-
SendGrid See it in the headers
Across Levels's email
- Sends
- About 3 a week
- DMARC
-
Enforced, reject
Mail failing authentication is refused.
The copy
411 words · about 2 min to read · 2 buttons
What one extra drink does to your night
The peptide boom is running ahead of the science
On October 28, HHS said it would stop taking action against licensed pharmacies that compound six popular peptides, including BPC-157 and TB-500, the pair sold online as the "Wolverine stack." For a market that's run on gray-market vials for years, that sounds like a turning point. To sort out what changed and what didn't, we sat down with Dr. Christopher Robinson, a Johns Hopkins physician-scientist who specializes in pain and regenerative medicine. Robinson calls himself pro-peptide and has applied for funding to test one. That's what makes his read on the evidence worth hearing.
Button The truth about peptides →
Five Key Takeaways
1. "Peptide" describes a size, not a breakthrough.
Any chain of 40 or fewer amino acids counts, so insulin, growth hormone, and GLP-1 drugs like semaglutide are all peptides. The compounds getting the buzz are a lightly studied corner of a very old category.
2. Human evidence for BPC-157 is nearly nonexistent.
Thirty years of animal research comes almost entirely from one lab in Croatia. Independent reviews count fewer than 30 people across all the human studies, and no randomized trial has been completed.
3. Many popular peptides are repurposed or abandoned drugs.
Tesamorelin is approved only to reduce abdominal fat in people with HIV-related lipodystrophy, and Melanotan II, sold for tanning, was abandoned in development before the wellness market picked it up. Using compounds like these for recovery or longevity goes well beyond what they were tested for.
4. The new policy still falls short of approval.
None of the six is FDA-approved or formally cleared for compounding, and the policy is interim. The FDA's own scientists had also recommended against all seven peptides its advisory panel reviewed. Still, a prescription from a licensed compounding pharmacy is safer than a "research use only" vial of unknown origin.
5. The trial that would settle it is simple and unfunded.
Robinson wants to test BPC-157 against a placebo for knee osteoarthritis. He'd measure function with wearables and cartilage with MRI, rather than relying on pain scores. Until data like that exists, his advice for friends and patients considering a peptide they find online or from a dude at the gym: don’t.
Button Read the full conversation →
Looking to understand more about your metabolic health?
Explore our health news and advice site, Metabolic Insights
228 Park Ave South, PMB 63877, New York, NY 10003
The words as text: what a screen reader can follow, and all there is when images don't load.
What the headers say
Read from the message's own headers, as it arrived.
- Came from
-
o24.sg.m.dripemail2.com
· 192.254.112.219
SendGrid's sending servers
- SPF
- Pass for drip.levels.com
- DKIM
-
- Pass signed by levels.com
- DMARC
-
Pass for levels.com
Policy: reject
- Unsubscribe
-
One-click
Meets the Gmail and Yahoo rule for bulk senders.
- Complaints
- No feedback-loop header
Show all 17 headers Hide the headers
As received, minus the delivery side: the archive's own addresses show as [recipient], its mail servers as [receiver], signatures are left out and unsubscribe links trimmed to their host.
Route
- Received
- from o24.sg.m.dripemail2.com (192.254.112.219) by [receiver] (cloudflare) id mZDcn1eSVplw for <[recipient]>; Thu, 19 Nov 2026 16:00:33 +0000
- Received
- by recvd-7fd4c8c657-zrk8z with SMTP id recvd-7fd4c8c657-zrk8z-1-6AFF1609-2D 2026-11-19 15:30:17.121062036 +0000 UTC m=+746273.402656237
- Received
- from MTMxMTA3NDc (unknown) by geopod-ismtpd-11 (SG) with HTTP id rSWItUiAR5GwvUB2WSoaVw Thu, 19 Nov 2026 15:30:17.100 +0000 (UTC)
Authentication
- Received-SPF Authentication result
- pass ([receiver]: domain of [email protected] designates 192.254.112.219 as permitted sender) receiver=[receiver]; client-ip=192.254.112.219; envelope-from="[recipient]@drip.levels.com"; helo=o24.sg.m.dripemail2.com;
- Authentication-Results Authentication result
- [receiver]; dkim=pass header.d=levels.com header.s=s1 header.b=SJVsGAkx; dmarc=pass header.from=levels.com policy.dmarc=reject; spf=none ([receiver]: no SPF records found for [email protected]) smtp.helo=o24.sg.m.dripemail2.com; spf=pass ([receiver]: domain of [email protected] designates 192.254.112.219 as permitted sender) smtp.mailfrom="[recipient]@drip.levels.com"; arc=none smtp.remote-ip=192.254.112.219
Platform
- X-Drip-SendingAccount
- 4080355
- X-SG-EID Identifies SendGrid
- u001.79kJZC85z/WE9t9nOmpiHosf7qU1Au+mrKy3jytIn8sMbSWRTgBdv9q1OykY6JKWUyE26878N4YhksNNJA9CVd+kedr9PsHLzXLtLLuobsuEPc/+gMorUaccn45Lot/m2nLURO9Dzl0N0EbDpobORW0MYeWNTHvlLxEgRfz7r2HFSvAZxfSXDSfBLIBbZrcMBWL5aHcHRsn6GHJEoqO3Z8QzCeYcNabtoGqZlr4PBJw=
- X-SG-ID Identifies SendGrid
- u001.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
- X-Entity-ID
- u001.dEl2Z4sQ4dqI57TjhSSBBA==
Unsubscribe and feedback
- List-Unsubscribe
- <mailto:…@unsubscribe.dripemail3.com>, <https://unsubscribe.dripemail3.com/…>
- List-Unsubscribe-Post
- List-Unsubscribe=One-Click
Message
- Content-Type
- multipart/alternative; boundary=0d004860f5560098edae0ec6b2295ff41209a1d8f2f3aa333d644c8fe328
- Date
- Thu, 19 Nov 2026 16:00:00 +0000 (UTC)
- From
- Levels <[email protected]>
- Mime-Version
- 1.0
- Message-ID
- <rSWItUiAR5GwvUB2WSoaVw@geopod-ismtpd-11>
- Subject
- Should you be taking peptides?
More from Levels
All 35 emailsSimilar campaigns from other brands
Different brands running the same play. Compare any of them side by side.
Archived for reference and commentary. Levels, its logos and content are the property of their respective owners; Inbox Archive claims no affiliation and has disabled all links. If you own this content and would like it removed, get in touch.